Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
- Monday, December 30, 2019, 7:00
- Finance
- Add a comment
INDIANAPOLIS, Dec. 30, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naïve RET-mutant medullary thyroid cancer (MTC) patients. This is the second…
About the Author
adminasapcorp has written 39093 stories on this site.